Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00518284 · ClinicalTrials.gov registry record · Phase 2
Prevention of Restenosis Following Revascularization
A Phase 2 study, sponsored by Celgene Corporation.
- Terminated
- Registry status
- Phase 2
- Development phase
- 6
- Enrollment target
NCT00518284: Clinical Trial Phase 2 study, sponsored by Celgene Corporation.
NCT00518284 is a Phase 2 study that was terminated before completion, run by Celgene Corporation. The registered enrollment target is 6 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00518284, a Phase 2 study, was terminated before completion, sponsored by Celgene Corporation.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 6 participants
- Enrollment target
Study Summary
The purpose of this study is to investigate the prevention of Restenosis following Revascularization of the superficial Femoral Artery (SFA)
Primary Outcome
Target vessel revascularization (TVR) was defined as percutaneous revascularization or bypass of the target lesion or any segment of the artery containing the target lesion. The percentage of participants requiring revascularization of the target vessel was determined by stenosis of \> 50% confirmed by angiography.
Interventions
- DRUG Nanoparticle Paclitaxel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2008-01 |
| Est. Completion | 2009-09 |
| Phase | Phase 2 |
Why NCT00518284 stopped before completion
NCT00518284 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 6 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (95% lower).
The record links to 0 conditions, and to 1 intervention - of which Nanoparticle Paclitaxel is the first listed.
NCT00518284 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00518284 about?
NCT00518284 is a clinical study titled "Prevention of Restenosis Following Revascularization". The purpose of this study is to investigate the prevention of Restenosis following Revascularization of the superficial Femoral Artery (SFA)
What is the current status of trial NCT00518284?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 6 participants. The study started on 2008-01. Estimated completion is 2009-09.
What interventions are being tested in trial NCT00518284?
The interventions under investigation include: Nanoparticle Paclitaxel (DRUG).
Who is sponsoring clinical trial NCT00518284?
This trial is sponsored by Celgene Corporation, which has 40 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00518284's enrollment target sits among peer trials
6 1996th of 2000 higher than 1 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia